✦ LIBER ✦

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

✍ Scribed by Paul J. Hesketh; David R. Gandara; Ann M. Hesketh; Anna Facada; Edith A. Perez; Lauri M. Webber; Lorene A. Martin; Michael B. Cramer; William F. Hahne

Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 619 KB
Volume: 4
Category: Article
ISSN: 0941-4355
DOI: 10.1007/bf01845763

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-ranging antiemetic evaluation of th

Dose-ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy

✍ Lorraine Baltzer; Mark G. Kris; Leslie B. Tyson; James R. Rigas; Katherine M. W. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

Background. RG 12915 is a potent, selective 5-HT3 receptor antagonist with a biologic half-life of 31-20 hours. RG 12915 prevents cisplatin-induced emesis in ferrets at doses of 0.03 mg/kg. Animal toxicology studies permitted safe testing in humans at doses of up to 2.0 mg/kg. This dose-ranging tria

Dose-ranging antiemetic evaluation of th

Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy

✍ Katherine M. W. Pisters; Mark G. Kris; Leslie B. Tyson; Rebecca A. Clark; Richar 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

Open-label comparison of the antiemetic

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

✍ Coppes, Max J.; Lau, Robert; Ingram, Lewis C.; Wiernikowski, John T.; Grant, Ron 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Background. Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure. An open-label dose-escalation study was conducted to assess the appropriate intravenous dose of dolasetron for pediatric patients undergoing chemotherapy. Patients received dolasetron in

Dose-ranging evaluation of the substitut

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy

✍ Stefan C. Grant; Mark G. Kris; Richard J. Gralla; Rebecca A. Clark; Leslie B. Ty 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 314 KB

Evaluation of risk factors predictive of

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

✍ David G. Warr; James C. Street; Alexandra D. Carides 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 152 KB

A randomized, double-blind comparison of

A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin

✍ Suzanne H. Stephens; V. Lee Silvey; Richard H. Wheeler 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 2 views

Thirty-seven patients with advanced incurable malignancies who were receiving their first course of cisplatin (2 90 mg/mz bolus), alone or in combination with other antineoplastic agents, were entered in this randomized, double-blind study to determine the antiemetic efficacy of the addition of high